Respiratory Morbidity and GAN Questionnaire
Throughout early follow-up, respiratory morbidity (inhaled
corticosteroids ≥ 3 consecutive months and/or respiratory-related
hospitalizations) was higher in the EP-BPD group than in other groups
(Table 1). In addition, respiratory morbidity differed between the
“high severity” and “low severity” BPD subgroups (E-table 5).
Moreover, the prevalence of lifetime wheezing episodes was higher in the
adolescents with BPD than in other adolescents, but differences only
reached statistical significance between EP-BPD and MLP groups after
adjusting for potential confounders. We found no significant differences
between groups either in current asthma prevalence or in the remaining
key questions of the GAN questionnaire (Table 3). There was no
association between BPD severity and asthma symptom prevalence (E-table
5).